Morana Jovan-Embiricos
Fortune : 2 M $ au 31/05/2026
Fortune : 2 M $ au 31/05/2026
Morana Jovan-Embiricos is the founder of F2 Capital Ventures LLP, founded in 2003, serving as Managing Partner.
Current jobs include Director at The Damon Runyon Cancer Research Foundation, Director at ElevateBio LLC, Director at Orna Therapeutics, Inc., Director at ReNAgade Therapeutics, Inc., and Independent Director at Kalaris Therapeutics, Inc. starting in 2025.
Former jobs include Independent Director at Radius Health, Inc. from 2014 to 2015, Independent Director at AlloVir, Inc., Director at TriNetX, LLC, Independent Director at TCR² Therapeutics, Inc. from 2015 to 2019, Director at Cullinan Oncology LLC, Director at Cullinan Therapeutics, Inc. from 2017 to 2021, Venture Partner at MPM BioImpact LLC, and Gérant at Banque SYZ SA. Education includes a doctorate from the University of Cambridge.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
1,81 % | 03/06/2026 | 431 663 ( 1,81 % ) | 2 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
F2 Capital Ventures LLP
F2 Capital Ventures LLP Investment ManagersFinance F2 Capital Ventures invests in companies located in the US and UK. The firm target companies operated in the field of healthcare services. It provides financing for early stage capital requirements. | Fondateur | 01/01/2003 |
The Damon Runyon Cancer Research Foundation
The Damon Runyon Cancer Research Foundation Miscellaneous Commercial ServicesCommercial Services Supports cancer research | Directeur/Membre du Conseil | - |
ElevateBio LLC
ElevateBio LLC BiotechnologyHealth Technology Operates as biotechnology holding company, which develops gene therapy and manufactures & commercializes life-transforming medicines | Directeur/Membre du Conseil | - |
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Develops RNA therapeutics | Directeur/Membre du Conseil | - |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Develops proprietary delivery technologies to unlock previously inaccessible cells | Directeur/Membre du Conseil | - |
| Sociétés | Poste | Fin |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Directeur/Membre du Conseil | 31/12/2021 |
| TCR2 THERAPEUTICS INC. | Directeur/Membre du Conseil | 01/05/2019 |
| RADIUS HEALTH, INC. | Directeur/Membre du Conseil | 27/02/2015 |
MPM BioImpact LLC
MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Private Equity Investor | 01/07/2006 |
| ░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 14 |
|---|---|
Radius Health, Inc.
Radius Health, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and commercializes bone health and related therapeutics | Health Technology |
MPM BioImpact LLC
MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Finance |
Banque SYZ SA
Banque SYZ SA Investment ManagersFinance Banque SYZ is primarily an active, benchmark-insensitive investor which employs a range of hedging techniques and utilizes alternative products, aiming to optimize risk and return. The firm only invests in areas where they perceive a genuine opportunity for gain and complements in-house expertise with external management for certain asset classes. They follow a two phase investment strategy consisting of asset allocation and stock-picking. Banque SYZ follows a bottom-up approach to select stock utilizing a value-driven philosophy which aims to identify undervalued companies. This process includes a company valuation program based on the assessment of fundamental characteristics of stocks via qualitative and quantitative analyses, which vary according to industry sectors. | Finance |
University of Cambridge
University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Damon Runyon Cancer Research Foundation
The Damon Runyon Cancer Research Foundation Miscellaneous Commercial ServicesCommercial Services Supports cancer research | Commercial Services |
F2 Capital Ventures LLP
F2 Capital Ventures LLP Investment ManagersFinance F2 Capital Ventures invests in companies located in the US and UK. The firm target companies operated in the field of healthcare services. It provides financing for early stage capital requirements. | Finance |
TriNetX, LLC
TriNetX, LLC Data Processing ServicesTechnology Services Provides healthcare and life science data & platform solutions | Technology Services |
TCR2 Therapeutics, Inc.
TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage cell therapy company which engages in the development of biological drugs and engineering T-cells for cancer therapy | Health Technology |
AlloVir, Inc.
AlloVir, Inc. BiotechnologyHealth Technology Develops cellular immunotherapies for severe infections | Health Technology |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Provides investment services for cancer treatments | Finance |
ElevateBio LLC
ElevateBio LLC BiotechnologyHealth Technology Operates as biotechnology holding company, which develops gene therapy and manufactures & commercializes life-transforming medicines | Health Technology |
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Develops RNA therapeutics | Health Technology |
Cullinan Oncology, Inc.
Cullinan Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Develops proprietary delivery technologies to unlock previously inaccessible cells | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national